https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-02 / Science 2015 May;348(6236):803-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-02 / Science 2015 May;348(6236):803-82015-04-02 00:00:002019-02-15 08:49:36Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-01 / Breast Care (Basel) 2015 Apr;10(2):109-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-01 / Breast Care (Basel) 2015 Apr;10(2):109-162015-04-01 00:00:002015-04-01 00:00:00Hyperthermia Is Now Included in the NCCN Clinical Practice Guidelines for Breast Cancer Recurrences: An Analysis of Existing Data
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-01 / Anticancer Res. 2015 Apr;35(4):2299-303
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-01 / Anticancer Res. 2015 Apr;35(4):2299-3032015-04-01 00:00:002015-04-01 00:00:00Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-27 / PLoS Pathog. 2015 Mar;11(3):e1004752
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-27 / PLoS Pathog. 2015 Mar;11(3):e10047522015-03-27 00:00:002019-02-15 08:48:01Decreased HIV-specific T-regulatory responses are associated with effective DC-vaccine induced immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-17 / Biol. Pharm. Bull. 2015;38(6):827-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-17 / Biol. Pharm. Bull. 2015;38(6):827-352015-03-17 00:00:002019-02-15 08:53:06Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-12 / Cancer Biother. Radiopharm. 2015 May;30(4):182-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-12 / Cancer Biother. Radiopharm. 2015 May;30(4):182-62015-03-12 00:00:002019-02-15 09:22:46Transplanted tumor growth and the incidence of T-lymphocyte populations in the spleen of newcastle virus-treated mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-11 / Nature 2015 Mar;519(7543):300-1
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-11 / Nature 2015 Mar;519(7543):300-12015-03-11 00:00:002019-02-15 08:39:32Cancer immunotherapy: dendritic-cell vaccines on the move
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-11 / Mol. Cancer Ther. 2015 May;14(5):1247-58
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-11 / Mol. Cancer Ther. 2015 May;14(5):1247-582015-03-11 00:00:002019-02-15 09:22:43Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-10 / Oncotarget 2015 Mar;6(7):5195-203
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-10 / Oncotarget 2015 Mar;6(7):5195-2032015-03-10 00:00:002019-02-15 08:45:08A novel cancer immunotherapy based on the combination of a synthetic carbohydrate-pulsed dendritic cell vaccine and glycoengineered cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-09 / Cancer Sci. 2015 Apr;106(4):397-406
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-09 / Cancer Sci. 2015 Apr;106(4):397-4062015-03-09 00:00:002019-02-15 08:52:27Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer
